Intelligence

Healthcare

Aspira Women's Health Announces Termination of ENDOinform Program Contract by ARPA-H

Author:
FAQsIR News Desk
Last Updated:
Reading Time
2 min

Aspira Women's Health Inc., headquartered in Austin, Texas, recently reported a critical development regarding its partnership with the Advanced Research Projects Agency for Health (ARPA-H). This partnership was established to support the advancement of women's health diagnostics through the ENDOinform program, aimed at enhancing non-invasive measures for endometriosis diagnosis.

#Termination of Development Contract

The ENDOinform program received an initial funding award of $10 million from ARPA-H to facilitate the creation of a blood-based diagnostic test utilizing advanced bio-analytics and artificial intelligence. The test is designed to leverage protein and microRNA biomarkers combined with patient-specific data to improve the diagnosis of endometriosis. However, on June 9, 2025, Aspira was informed that ARPA-H, in conjunction with its managing contractor, VentureWell, found that the company had not satisfied the criteria set forth in Milestone 3 of their agreement. As a result, the contract for the ENDOinform development program was terminated.

#Company Response and Future Plans

In a statement reflecting on the contract termination, CEO Mike Buhle expressed disappointment but emphasized the team's belief in their achievements related to the project. Buhle noted that the team had met the requirements for Milestone 3 ahead of schedule and were making preparations to meet the subsequent milestones. He reaffirmed the company's commitment to moving forward with the ENDOinform project, aiming for a completion target in 2026.

Aspira intends to resume development independently, relying on support from shareholders and collaboration partners. The company remains optimistic about the potential impact of ENDOinform on the lives of women suffering from endometriosis, asserting its goal of improving health outcomes and quality of life through non-invasive diagnostics.

#Background on ENDOinform

The ENDOinform test represents a significant advancement in the non-invasive detection of endometriosis, a condition that affects millions of women globally. By using pioneering technology developed from previous ovarian cancer diagnostics, Aspira aims to facilitate better clinical decision-making for patients experiencing symptoms associated with endometriosis. The company previously started receiving payments against the ARPA-H funding, amounting to $3.5 million, before the contract termination.

#Key Takeaways

  • Aspira Women's Health's ENDOinform development contract with ARPA-H has been terminated due to unmet specifications.
  • CEO Mike Buhle expressed confidence in the team's progress and commitment to continue the project's development independently.
  • The ENDOinform test aims to advance non-invasive diagnostics for endometriosis, with a targeted completion date of 2026.
  • Aspira has historically engaged in innovative women's health diagnostics, including ovarian cancer risk assessments.
  • The company's future plans include seeking alternative support to enhance women's health through its ongoing research initiatives.

Original source: Read original article

Frequently Asked Questions

Aspira Women's Health announced a recent update where ARPA-H terminated the development program contract for the ENDOinform test, citing unmet specifications. However, Aspira's management indicated confidence in their achieved milestones and plans to continue development independently, emphasising the potential importance of the ENDOinform project for women's health.
The ENDOinform test represents a pioneering effort to provide non-invasive diagnostic capabilities for endometriosis, a condition affecting millions of women. Given its novel application of AI and multi-omics technology, its successful development could greatly enhance current diagnostic methods and improve patient outcomes.
While the termination of the contract may seem discouraging, Aspira's management insists that they continue to meet project milestones and are confident about future advancements. This could suggest that the company might pursue alternative funding or strategies to continue their pivotal work in women's health diagnostics.
Aspira initially received $3.5 million of the awarded $10 million through ARPA-H, underscoring the initial recognition of their potential within the women’s health sector. The company’s ongoing activities may still attract further investments or partnerships to continue its development goals.
Aspira's technology, particularly its multi-omics approach, holds significant promise for improving the accuracy of diagnosing endometriosis. This could lead to earlier and more effective management of the condition, thereby potentially improving the quality of life for affected individuals.
Aspira plans to press on with its development of the ENDOinform programme independently, confident in its R&D capabilities. This strategic pivot could facilitate a focused approach to meet their goals for enhancing women's health diagnostics.
The market might exhibit a nuanced reaction to Aspira's recent challenges; however, the continued commitment to innovation in women's health and the potential success of the ENDOinform project could ultimately sustain investor interest and confidence in the company's long-term objectives.
The collaboration with ARPA-H highlighted the crucial unmet needs in women's health, and despite the contract's termination, it has positioned Aspira to remain at the forefront of developing non-invasive diagnostics. This ongoing focus may foster advancement in women's health research and improve overall health outcomes.